<DOC>
	<DOCNO>NCT00732043</DOCNO>
	<brief_summary>High concentration anti-oxidants pomegranate seed present potential strategy delay clinical prostate cancer progression prolong interval primary treatment failure hormonal ablation . This 48 month extension double-blind GUP-0205-1 study , compare effect daily consumption pomegranate liquid extract versus placebo absolute prostate-specific antigen ( PSA ) double time end 12 , 24 , 36 48 month male subject rolled-over GUP-0205-1 study .</brief_summary>
	<brief_title>Extension Study Effects Pomegranate Extract Rising PSA Levels After Primary Therapy Prostate Cancer</brief_title>
	<detailed_description>The primary objective compare effect daily consumption pomegranate liquid extract versus placebo absolute prostate-specific antigen ( PSA ) double time end 12,24 , 36 48 month male subject rolled-over GUP-0205-1 study . Secondary objective determine effect pomegranate treatment change PSA doubling time baseline 12-month visit , determine time tumor recurrence , assess tolerability toxicity pomegranate treatment determine effect pomegranate treatment response rate positive PSA double time decline post-treatment PSA level ( negative double time ) .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>No evidence disease progression three GUP0205 study product ( disease progression define &gt; 100 % increase serum PSA [ minimum value 1.0 ng/mL ] ) . Willingness ability sign inform consent document . Agreement complete abstinence commercially available pomegranate product course study . Use dietary/herbal supplement ( e.g. , saw palmetto , selenium , etc ) acceptable provide dose stable course GUP0205 1 study . Significant concomitant medical psychiatric condition , opinion Principal Investigator , would put subject risk compromise protocol . Hormonal therapy , exception neoadjuvant androgen deprivation therapy ( ADT ) prior concurrent primary therapy . Subjects underwent neoadjuvant ADT serum testosterone â‰¤150 ng/mL study entry . Concomitant antecedent hormonal therapy rise serum PSA initial therapy prostate cancer . Subjects unable unwilling comply protocol requirement . Prior treatment experimental drug , high dose steroid , cancer treatment within 4 week prior first dose study product duration study . Serum PSA &gt; 7.0 ng/mL ( assessed termination doubleblind study ; PSA level , subject exclude determined Principal Investigator subject 's continued participation would best interest ) . Serum PSA double time &lt; 13 week ( assessed termination doubleblind study ) . Evidence metastatic disease physical examination CT bone scan . Use finasteride , dutasteride point since primary therapy study . Clinically significant abnormal laboratory value great 2 time upper limit normal ( &gt; 2XULN ) .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>prostate cancer</keyword>
	<keyword>prostate-specific antigen</keyword>
	<keyword>PSA</keyword>
	<keyword>pomegranate</keyword>
</DOC>